Search
15 result(s) for 'author#Laura M Heiser' within BMC
Page 1 of 1
Sort by: Relevance | Date
-
Citation: Breast Cancer Research 2017 19:17
-
The adaptation and evaluation of a CBT-based manual for the inpatient treatment of youth depression: a pilot study
Although there is good evidence to support the effectiveness of cognitive behavioral therapy (CBT) for the outpatient treatment of adolescent major depressive disorder (MDD), evidence-based manuals for the inp...
Citation: Pilot and Feasibility Studies 2020 6:30 -
Erratum to: Modeling precision treatment of breast cancer
During the type-setting of the final version of the article [1] some of the additional files were swapped. The correct files are republished in this Erratum.
Citation: Genome Biology 2015 16:95 -
Analysis of molecular inversion probe performance for allele copy number determination
We have developed a new protocol for using molecular inversion probes to accurately and specifically measure allele copy number. The new protocol provides for significant improvements, including the reduction ...
Citation: Genome Biology 2007 8:R246 -
Modeling precision treatment of breast cancer
First-generation molecular profiles for human breast cancers have enabled the identification of features that can predict therapeutic response; however, little is known about how the various data types can bes...
Citation: Genome Biology 2013 14:R110 -
Annot: a Django-based sample, reagent, and experiment metadata tracking system
In biological experiments, comprehensive experimental metadata tracking – which comprises experiment, reagent, and protocol annotation with controlled vocabulary from established ontologies – remains a challen...
Citation: BMC Bioinformatics 2019 20:542 -
The Resident Assessment Instrument-Minimum Data Set 2.0 quality indicators: a systematic review
The Resident Assessment Instrument-Minimum Data Set (RAI-MDS) 2.0 is designed to collect the minimum amount of data to guide care planning and monitoring for residents in long-term care settings. These data ha...
Citation: BMC Health Services Research 2010 10:166 -
Integrated analysis of breast cancer cell lines reveals unique signaling pathways
Cancer is a heterogeneous disease resulting from the accumulation of genetic defects that negatively impact control of cell division, motility, adhesion and apoptosis. Deregulation in signaling along the EgfR-...
Citation: Genome Biology 2009 10:R31 -
A robust prognostic signature for hormone-positive node-negative breast cancer
Systemic chemotherapy in the adjuvant setting can cure breast cancer in some patients that would otherwise recur with incurable, metastatic disease. However, since only a fraction of patients would have recurr...
Citation: Genome Medicine 2013 5:92 -
Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
Triple negative breast cancer (TNBC) is a highly heterogeneous and aggressive type of cancer that lacks effective targeted therapy. Despite detailed molecular profiling, no targeted therapy has been establishe...
Citation: Molecular Cancer 2016 15:34 -
A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047
Polyamines regulate important cellular functions and polyamine dysregulation frequently occurs in cancer. The objective of this study was to use a systems approach to study the relative effects of PG-11047, a ...
Citation: BMC Medicine 2009 7:77 -
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
Activation of the phosphatidylinositol 3-kinase (PI3K) pathway in estrogen receptor α (ER)-positive breast cancer is associated with reduced ER expression and activity, luminal B subtype, and poor outcome. Pho...
Citation: Breast Cancer Research 2014 16:430 -
Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA
HER2-amplified breast cancer is a clinically defined subtype of breast cancer for which there are multiple viable targeted therapies. Resistance to these targeted therapies is a common problem, but the mechanisms...
Citation: Breast Cancer Research 2021 23:81 -
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer
High mitotic activity is associated with the genesis and progression of many cancers. Small molecule inhibitors of mitotic apparatus proteins are now being developed and evaluated clinically as anticancer agen...
Citation: Breast Cancer Research 2016 18:70 -
Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes
The growth factor receptor network (GFRN) plays a significant role in driving key oncogenic processes. However, assessment of global GFRN activity is challenging due to complex crosstalk among GFRN components,...
Citation: Genome Medicine 2017 9:40